Hytrin 5 (Terazosin Hydrochloride Dihydrate)

Terazosin works by selectively blocking alpha‑1 adrenergic receptors on blood vessels and in the prostate. This blockade prevents norepinephrine‑induced contraction, causing blood vessels to dilate and reducing peripheral resistance, and it also relaxes smooth muscle in the urinary tract, easing urinary obstruction.

The exact dose of Hytrin 5 is determined by the prescribing clinician based on the individual’s medical condition, response, and tolerability. Physicians typically start with a low dose and may adjust it gradually to achieve the desired blood‑pressure control or symptom relief.

Safety data for terazosin in pregnancy and lactation are limited, and the drug is generally not recommended for use in pregnant or nursing women unless the potential benefit outweighs the risk. Physicians should evaluate each case carefully before prescribing.

To request Hytrin 5, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Hytrin 5 (terazosin) is an older, non‑selective alpha‑1 blocker, offering both antihypertensive and BPH benefits. Compared with newer agents such as tamsulosin, which is more prostate‑selective, terazosin may cause more systemic blood‑pressure effects but can be advantageous when both hypertension and BPH need treatment.

Hytrin 5 should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Hytrin 5 is taken orally, usually as a whole tablet swallowed with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any specific dietary considerations.

The most serious risks include severe hypotension, syncope, and priapism. Patients should be alert for sudden dizziness, fainting spells, or a prolonged erection lasting more than four hours, and seek immediate medical attention if these events occur.

Hytrin 5 should be avoided in individuals with known hypersensitivity to terazosin or any component of the formulation, in patients with severe liver disease, and in those who have experienced severe hypotension or syncope with prior alpha‑blocker therapy. A healthcare professional must evaluate suitability before prescribing.